MLN3126 / Takeda - LARVOL DELTA

MLN3126, an antagonist of the chemokine receptor CCR9, ameliorates inflammation in a T cell mediated mouse colitis model. (PubMed, Int Immunopharmacol) - "Anti-TNF-α antibody, a surrogate for a standard of care for IBD treatment, was also efficacious in the colitis model. These results suggest that MLN3126 would be a promising orally available CCR9 antagonist to treat colonic IBD."

Journal • Preclinical • Biosimilar • Immunology • Inflammation • Inflammatory Bowel Disease

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants (clinicaltrials.gov) - P1; N=23; Terminated; Sponsor: Takeda; N=64 -> 23 ; Suspended -> Terminated ; Trial primary completion date: Mar 2015 ->Oct 2014

Enrollment change • Trial primary completion date • Trial termination • Biosimilar